Accession Number | HMDB00543 |
Common_Name | Benzenebutanoic acid |
Description | 4-phenylbutyrate (4-PBA) is known to be a transcriptional regulator, and sodium-4-PBA has been shown to induce fetal hemoglobin, and it has been used in clinical trials for sickle cell anemia and β-thalassemia Because gene expression profiles became more differentiated, it is in phase I trials in several different malignant disorders. The potential for therapeutic benefit in cystic fibrosis (CF) resides in an additional mechanism, involving protein folding and the ER environment. 4-PBA is a drug that was developed to treat elevated blood ammonia in urea cycle disorders, a histone deacetylase inhibitor that promotes mutation ΔF508 cystic fibrosis transmembrane conductance regulator (CFTR) trafficking. (PMID 12458151) |
Chemical_IUPAC_Name | 4-phenylbutanoic acid |
Chemical Formula | C10H12O2 |
Sample Concentration | Not Available |
Mass Value | Not Available |
Mass Unit | mg |
Manufacturer | Quattro_QQQ |
Analyzer | Triple_Quad |
Delivery | Flow_Injection |
Ionization | Negative |
Predicted 1H NMR Spectrum | Download |
Predicted 1H NMR Peaklist | Download |
Predicted 13C NMR Spectrum | Download |
Predicted 13C NMR Peaklist | Download |
Sample Concentration | Not Available |
Mass Value | Not Available |
Mass Unit | Not Available |
Manufacturer | Not Available |
Frequency | Not Available |
1H NMR Spectrum | ![]() |
Sample Concentration | Not Available |
Mass Value | Not Available |
Mass Unit | Not Available |
Manufacturer | Not Available |
Frequency | Not Available |
13C NMR Spectrum | Not Available |
Low Energy Voltage | 10 |
Low Energy Spectrum | Download |
Low Energy Peaklist | Download |
Medium Energy Spectrum | Download |
High Energy Spectrum | Download |